Prospera Financial Services Inc. reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 38.0% during the third quarter, now holding 8,766 shares valued at $4.93 million. This portfolio adjustment comes despite Regeneron reporting a significant beat on its third-quarter earnings expectations. The company posted an EPS of $11.44 and revenues of $3.88 billion, surpassing analyst estimates. Furthermore, Regeneron increased its quarterly dividend, signaling robust financial performance. Analysts maintain a "Moderate Buy" consensus rating for the stock, with a target price of $793.81. These developments present mixed signals for investors, balancing institutional portfolio adjustments against strong underlying company fundamentals.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis